CORRECTION

Open Access

Check for updates

Correction: Revisiting gliomatosis cerebri in adult-type diffuse gliomas: a comprehensive imaging, genomic and clinical analysis

Ilah Shin¹, Yae Won Park^{2*}, Yongsik Sim², Seo Hee Choi³, Sung Soo Ahn², Jong Hee Chang⁴, Se Hoon Kim⁵, Seung-Koo Lee² and Rajan Jain^{6,7}

Correction: Acta Neuropathologica Communications (2024) 12:128

https://doi.org/10.1186/s40478-024-01832-w

Following publication of the original article [1], the author found that the affiliation details for author Ilah Shin were incorrectly given as Ilah $Shin^{1,2}$ but should

have been Ilah Shin¹. The second affiliation, "Department of Statistics and Data Science, Yonsei University, 50 Yonsei-ro, Sedaemun-gu, Seoul, 03722, Republic of Korea" has been deleted, and the affiliation order has been renumbered. And, there is a misalignment in Fig. 1 and the resolution of figures 2 and 3 needs to be improved.

(See figure on next page.)

Fig. 1 Patient characteristics of the study cohort of adult diffuse glioma patients of our institution. **A** Flow chart of patient inclusion. **B** Representative imaging and histologic findings in a patient with IDH-wildtype glioblastoma showing GC. On MRI, a diffuse infiltrative glioma involving bilateral cerebral hemispheres is seen on FLAIR image. Faint enhancement is seen in some areas on postcontrast T1-weighted image. On low-power view (H&E; × 1.25), glioma cells are diffusely infiltrated into the cerebral parenchyma, suggesting GC. **C** Pie charts summarizing the distribution of molecular types of the adult-type diffuse glioma in patients with and without GC. **D** Summary plot of the clinical, molecular and imaging findings of patients with GC. GC = gliomatosis cerebri; IDH = isocitrate dehydrogenase; *MGMT* = O6-methylguanine-methyltransferase, NOS = not otherwise specified, NEC = not elsewhere classified, CE = contrast-enhancing, *TERT*p = telomerase reverse transcriptase promoter, = epidermal growth factor receptor

The original article can be found online at https://doi.org/10.1186/s40478-024-01832-w.

*Correspondence:

Yae Won Park

yaewonpark@yuhs.ac

¹ Department of Radiology, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, 222 Banpo-daero, Seocho-gu, Seoul 06591, Republic of Korea

² Department of Radiology and Research Institute of Radiological Science and Center for Clinical Imaging Data Science, College of Medicine, Yonsei University, 50 Yonsei-ro, Sedaemun-gu, Seoul 03722, Republic of Korea ³ Department of Radiation Oncology, Yonsei University College of Medicine, 50 Yonsei-ro, Sedaemun-gu, Seoul 03722, Republic of Korea
⁴ Department of Neurosurgery, Yonsei University College of Medicine, 50 Yonsei-ro, Sedaemun-gu, Seoul 03722, Republic of Korea

- ⁵ Department of Pathology, Yonsei University College of Medicine, 50 Yonsei-ro, Sedaemun-gu, Seoul 03722, Republic of Korea
- ⁶ Department of Radiology, New York University Grossman School
- of Medicine, 550 1 Ave, New York, NY States, USA
- ⁷ Department of Neurosurgery, New York University Grossman School of Medicine, 550 1 Ave, New York, NY States, USA



© The Author(s) 2024. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Incorrect Figure 1





Fig. 1 (See legend on previous page.)



Fig. 2 Representative imaging cases of GC cases with correctly **A**, **B** and incorrectly **C**, **D** predicted IDH mutation status according to multivariable model. **A** A 59-year-old male with IDH-mutant astrocytoma, CNS WHO grade 3. MRI shows a non-enhancing diffuse infiltrative tumor involving bilateral frontal lobes, left basal ganglia, and left thalamus. There is no discrete tumor mass, indicating type 1 GC. Cystic changes are seen at the left frontal lobe (arrows) on T2-weighted and FLAIR images. There is no hemorrhage on gradient recalled echo (GRE)-weighted image and no cellularity increase on apparent diffusion coefficient (ADC) map. **B** A 60-year-old female with IDH-wildtype glioblastoma, CNS WHO grade 4. MRI shows a non-enhancing diffuse infiltrative tumor involving the bilateral parietotemporoccipital lobes. There are obvious contrast-enhancing tumor masses, indicating type 2 GC. Contrast-enhancing necrotic tumor portions are seen at the right temporal and left parietotemporal lobes. There is a focal cellularity increase of solid enhancing tumor portions on ADC map. **C** A 65-year-old female with IDH-mutant astrocytoma, CNS WHO grade 2 showing a non-enhancing diffuse in-filtrative tumor without necrosis, cystic change, nor hemorrhage. **D** A 32-year-old male with IDH-wildtype glioblastoma, CNS WHO grade 4. This patient was histologically grade 2, but was classified as IDH-wildtype glioblastoma due to presence of *TERT*p mutation (molecular glioblastoma). This case also shows imaging finding of a non-enhancing diffuse infiltrative tumor without necrosis, cystic change, nor hemorrhage



(a) Entire adult-type diffuse glioma patients

Fig. 3 Kaplan–Meier curves of the OS of the according to the presence of GC in the **a** entire adult-type diffuse glioma patients and **b** IDH-wildtype glioblastoma patients. GC = gliomatosis cerebri; IDH = isocitrate dehydrogenase

The original article has been corrected.

Published online: 06 November 2024

Reference

 Shin I, Park YW, Sim Y et al (2024) Revisiting gliomatosis cerebri in adulttype diffuse gliomas: a comprehensive imaging, genomic and clinical analysis. Acta Neuropathol Commun 12:128. https://doi.org/10.1186/ s40478-024-01832-w

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

(b) IDH-wildtype glioblastoma patients